H

ello, everyone, and nice to see you again after the extended holiday break. We reveled in some rare time with our short people and we hope your own mini-break was relaxing and fun, especially since the oh-so-familiar routine of meetings, deadlines, and what-not is poised to return with a vengeance. You knew this was coming, yes? So what better way to cope than with a fresh cup of stimulation? We are quaffing vanilla cinnamon, for those who track this sort of thing. Meanwhile, we are playing catchup, not surprisingly, and have provided some tidbits that span several days. Hope your day goes well and you ease in gracefully. …

Drug and device makers accounted for more than $900 million of $3.7 billion in settlements and judgments from civil cases involving fraud and false claims against the government in the fiscal year ending Sept. 30, 2017, according to the feds. Shire (SHPG) paid $350 million to resolve allegations of paying kickbacks and illegally marketing a medicine, while Mylan paid $465 million to resolve allegations that it underpaid rebates owed under the Medicaid Drug Rebate Program for EpiPen.

Unlock this article by subscribing to STAT Plus today. Try it FREE for 30 days and cancel anytime!

SUBSCRIBE TODAY

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • GOOD! IWANT PHARMA BROUGHT DOWN TO APPRECIATE ALL THE MONEY IT GOT FROM POISONING AMERICANS< KILLING< AND MAKING CHEAP BIOSIMILIARS < THAT ARE NOT! AND HAVING PAY THE SAME PRICE FOR A BRANDNAME ORIGINAL OF MODERN DAY FOR CHEAP 30 yr old CRAP! I WANT MY BRANDNAME <2010 SYNTHROID BRANDNAME THE F BACK WITH90 to 110% POTENCY AND FDA TO OVER SEE TO MAKE SURE THEY DO IT< EVERY PILL! FOR THYROID PATIENTS HAVE SUFFERED THE WORST FOR THEIR CRAP GREED and we deserve the damb PILL BACK and PAY WHAT WE PAY NOW AND NO MORE FOR THE REAL BRANDNAME DAMB IT! WE SHOULD HAVE THE SAME DAMB PILL EVERY DAY TOO AND THAT MEANS PUT THE DAMB PATENTS PROTECTIONS THE F BACK INPLACE

  • NASH is epidemic. There is a good reason for the shortage of trial subjects– the requirement to undergo a liver biopsy. This can be COMPLETELY avoided by the use of imaging techniques that can estimate liver fat content. My guess is that FDA is making companies confirm the NASH via liver biopsy, hence the patient shortage.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

Privacy Policy